Weekly Trader

Upcoming Market Opportunities and Events

Monday, 15th October 2018

Key Themes This Week

The Week Ahead

In what will be an exceptionally busy week for Brussels, we expect European markets to be volatile as a number of events develop over the week. Firstly, we will be watching the fallout from the Bavarian election in Germany. Mrs Merkel's strongest ally in the region, the CSU, suffered its worst performance since 1950, losing an absolute majority, while its Junior collation partner, the Social Democrats, secured only 9.7% of the vote. These results significantly weaken Mr Merkel's coalition and will heighten risks associated with equity markets. The more pressing matters this week will be Brexit and the Italian budget approval. Mrs May called the EU's draft treaty a "non-starter" creating a stand off between the two blocs in advance of Wednesday's European Council meeting. While, Italy has submitted its draft budget to the EU for approval with an Italian cabinet meeting scheduled for this evening. Political uncertainty has weighed on European markets all year, with this weeks issues a continuation of that trend. Having two such contentious issues driving markets this week we expect market volatility to be higher. Looking at US markets which continued strong earnings data during the week should drive outperformance versus Europe.

Greencore to sell entire US business

Greencore announced this morning that it will be selling the entire US side of the business to Hearthside for \$1.075bn on a cash and debt free basis. This represents a healthy valuation of 13.4x EV/EBITDA. It marks a premium on the original \$747.5m paid for Peacock Foods and total invested capital of the US of \$979m. The total valuation of the sale represents 41% of Greencore's estimated enterprise value. The net proceeds of £802m will be split between £509m of a special dividend and £293m used to reduce debt. The special dividend of 72p per share represents 35% market cap of the business. Greencore will now compromise solely of the UK/Ireland business. In our opinion the remaining UK/Ireland business faces some structural and secular headwinds. Despite the "food to go" segment showing solid growth, it is becoming a saturated market (Greencore owns 60% of the sandwich market) with significant concentration risk and pricing pressures. In our view the US side of the business represented the growth potential. The stock has fallen by 5% on the back of the sale. Along with the news of the sale, management have reiterated guidance of an adjusted EPS of 14.7p - 15.7p for FY18. We are moving Greencore to Under Review from Outperform. The price target of 207p will likely change. Management is holding a call at 9.30am today.

Earning Season kicked off on Friday with JP Morgan, Wells and Citi

JP Morgan: Friday's results beat analysts expectations with Net Revenues coming in marginally down on Q2 but ahead of expectations at \$27.8bn. Net interest income from lending was the big positive, coming in at \$13.9bn on the back of higher rates and 6% growth in core loans. Elsewhere fixed income revenues were down 10% with equity market revenues up 17%. Strong revenue growth fed into the bottom line, with reported earnings per share (EPS) at \$2.34 ahead of expectations of \$2.26.

Wells Fargo: Wells posted a slight beat on revenues for Q3 coming in at \$21.9 (versus est. of \$21.8bn). However, loan growth disappointed with total loans down almost \$2bn to \$942bn. Net interest income and net interest margin were flat on the previous quarter coming in at \$12.6bn and 2.94%. EPS disappointed coming in at \$1.13 versus expectation of \$1.20. WFC returned almost \$9bn to shareholders through buybacks and dividends in the quarter.

Citigroup: Citi posted flat revenues on the previous quarter coming in at \$18.4bn meeting analysts consensus forecast. Fixed income posted strong gains, while investment banking revenue were 17% weaker than Q2. Consumer banking posted 5% revenue gains, with retail banking performing strongly. Total loans were up 3% to \$675bn. EPS missed expectations coming in at \$1.63 versus expectations of \$1.69.

This week we cover off on DCC, Vinci, Irish Foods and Healthcare.


Major Markets Last Week Value Change % Move 25340 Dow -1107 -4.19% S&P 2767 -118.44 -4.10% 7497 -291.55 Nasdaq -3.74% UK Index 7013 -220.13 -3.04% DAX 11524 -423.35 -3.54% ISEQ 6098 -290.60 -4.55% Nikkei 22271 -1512 -6.36% H.Seng 25472 -730.43 -2.79% STOXX600 359 -13.51 -3.63% Brent Oil 81.24 -2.67 -3.18% Crude Oil 71.79 -2 50 -3.37% 37.70 Gold 1226 3.17% Silver 14.6815 0.31 2.16% 280.2 3.50 1.26% Copper **CRB** Index 417.66 0.37 0.09% Euro/USD 1.1567 0.01 0.65% Euro/GBP 0.8818 0.00 0.45% GBP/USD 1.3118 0.00 0.21% Value Change German 10 Year 0.493 -0.04 UK 10 Year 1.618 -0.06 US 10 Year 3.1519 -0.08 0.00 Irish 10 Year 1.054 Spain 10 Year 1.675 0.08 Italy 10 Year 3.551 -0.02 BoE 0.75 0.00 ECB 0.00 0.00 Fed 2.25 0.00

All data sourced from Bloomberg

Opportunities this week

CFI Research Team

DCC



Key Metrics	2018e	2019e	2020e
Revenue (£'Mn)	15398.1	15741.7	15989.3
EPS (£)	3.66	3.83	3.94
Price/ Earnings	17.42x	16.66x	16.18x
Div Yield	2.12%	2.26%	2.44%

Source: All data & charts from Bloomberg & CFI

Share Price Return	1 Mth	3 Mth	YTD
DCC LN	-8.12%	-6.92%	-14.4%

Source: All data & charts from Bloomberg & CFI



Key Metrics	2018e	2019e	2020e
Revenue (€'Mn)	42835.0	44347.7	45801.6
EPS (€)	5.38	5.82	6.39
Price/ Earnings	14.3x	13.21x	12.05x
Div Yield	3.47%	3.75%	4.10%
Source: All data & charts from Bloomberg & CFI			

oodroo. All data a charto nom Dicombolg a of t				
Share Price Return	1 Mth	3 Mth	YTD	
DG FP	-4.84%	-9.66%	-9.52%	
Source: All data & shorts from Ploomborg & CEI				

Source: All data & charts from Bloomberg & CFI

Closing Price: 6390 GBp

- Has traded down by 12.5% from the trading update/ stock placing on the 27th of September. This extent of this fall is unwarranted.
- Given DCC's impressive balance sheet, with a net debt /ebitda of 1.1x, last weeks 10% (8.9m share) equity raise reflects managements ambitions for further growth. We therefore expect further deals to be announced over the coming months.
- We see further potential for acquisitions across all 4 divisions (LPG, Retail & Oil, Tech and Healthcare). It operations in extremely fragmented markets with significant opportunity.
- M&A continues to accelerate. Spending £270 in H1 vs £448 on average annually for the past three years.
- Prior to interim results in November, Thursdays pre close trading update, confirmed another acquisition and both profit growth for the first half of the year and into the next half. With all segments performing.
 - * The acquisition of Jam Group looks to be another prudent investment achieved at a reasonable price. Offering above market growth (4%-5% vs 2%-3%), a high return on capital (15%) and further expansion into North American technology.
- Brexit remains the most significant headwind.
- Despite the 10% equity raise there has been no change to the consensus price target of £84.94. Implying 33% upside.
- Market sees significant growth this year
 - * 15.26% EPS growth
 - * 8.36% EBITDA growth
 - * 10% Dividend per share growth
- High conviction in this stock. Maintain Outperform Rating.

Closing Price: €77.04

Remains one of the best infrastructure companies globally with above sector average earnings growth.

- FY18 Est. 10.01% earnings growth
- FY19 Est. 8.24% earnings growth
- FY20 Est. 9.65% earnings growth

One of the largest infrastructure portfolios with global exposures, with traffic figures supporting strong revenue growth

Vinci model has some very attractive characteristics

- Defensive and growth story in one
- Less correlated to traditional equities
- * Substantial upside optionality stemming from Macron privatisation program
- * CapEx cycle ending this year, implying better cash flow and dividend increases
- Very strong balance sheet (€2.6bn in cash), div yield of 3.1%.
- France's domestic dependency along with accommodative government policy should support CAC outperformance in Europe.
 - * Increasing political uncertainty in France (Macron has lost three ministers) could destabilise French economic outlook. This would hurt Vinci's concession business revenues.
- It is currently trading at €77.20, representing 27% upside to consensus price target of €98.15. Our own price target is €101.5, representing 31% upside.
- Trading at year to date lows, at current levels twice once in February and once in March. We expect it to hold these levels and rerate higher on its earnings announcement on the 23/10/2018.

Opportunities this week

CFI Research Team

Irish Foods



Key Metrics	2018e	2019e	2020e
Revenue (€'Mn)	2352.8	2460.9	2601.7
EPS (€)	0.86	0.93	0.99
Price/ Earnings	16.71x	15.51x	14.55x
Div Yield	1.70%	1.85%	2.01%

Source: All data & charts from Bloomberg & CFI

Share Price Return	1 Mth	3 Mth	YTD
GLB ID	-2.31%	-6.75%	-3.62%

Source: All data & charts from Bloomberg & CFI

HealthCare



Key Metrics	2018e	2019e	2020e
Revenue (€'Mn)	225429.1	243895	264957
EPS (€)	12.70	14.41	16.28
Price/ Earnings	20.43x	18.02x	15.94x
Div Yield	1.33%	1.47%	1.56%

Source: All data & charts from Bloomberg & CFI

Share Price Return	1 Mth	3 Mth	YTD
UNH US	-0.55%	1.97%	17.76%

Source: All data & charts from Bloomberg & CFI

Closing Price: €14.36

Glanbia - Reports Q3/18 trading update on the 01/11/2018

- Glanbia has moved in downward trend since reporting H1/18 earnings at the beginning of August. Despite coming in line with expectations slower volume growth and tightening margins made the market question guidance.
- However it has consistently guided as a <u>H2/18 story</u> and management remains very confident in <u>meeting expectations</u>.
 - EPS growth 5%-8% at constant currency
 - Mid to high single digit volume growth in GPN and GN
 - Margin recovery to FY17 levels (15% GPN/ 9% GN)
- The <u>CMD</u> in June highlighted managements ambitions for significant growth over the medium term.
- Last weeks acquisition of <u>Slimfast</u>. Looks to be another positive purchase, that helps expand its RTD and RTM range. While maintaining a healthy level of debt (1.7x EBITDA).
- Glanbia is currently trading at a 17% discount to both its history and the broader sector. 18.6% upside to consensus.
- Kerry Group Reports Q3/18 trading update on the 07/11/2018
 - Kerry remains one of our preferred stocks in the sector displaying superior growth, a diversified innovative product range and the ability to pass through cost inflation
 - Solid <u>H1/18</u> results upgrading EPS (7%-10%) guidance
 - Continues to deliver on medium term plan (10% EPS growth, 3%-5% volume growth, 30bps margin improvement)
 - Maintain our Outperform rating and continue to advise clients to pick up the stock. Consensus price target of €98.06.

Closing Price: \$259.61

Despite being the outperforming sector YTD, (US healthcare 10%) we continue to <u>advise clients</u> to pick up healthcare stocks Possesses defensive characteristics and secular tailwinds with the track record of performing during periods of high volatility, late cycle

and recessionary environments.

Two of our preferred names in the healthcare space remain UnitedHealth Group and GlaxoSmithKline

UnitedHealth Group - Reports Q3/18 earnings 16/10/2018

- We reiterate last weeks call in the <u>Trader</u> and advise buying both as a defensive play and/or into results on Tuesday.
- Expect to beat on earnings again which it has done every quarter since 2009.
- Will provide some guidance for 2019 (13% EPS expected). Expect an upbeat tone given <u>Q2 commentary</u>.
- Added to our core portfolio on 01/10/2018

GlaxoSmithKline - Reports Q3/18 earnings on 31/10/2018

- Leading pharmaceutical company that has benefited this year from the delay of the generic advair, Novartis Consumer minority buyout and strength of Shingrix
- Offers long term sustainability, product/geographical diversity and a dividend yield of 5.5%.
- Undergone significant cultural shift under new CEO with an increased focus on R&D.
- Trades at a considerable discount to peers (12x vs 14x).
- Has dropped to from £16.20 to £14.50. Leaving 14% upside to consensus price target of £16.46. Expect it to rerate.

Cantor Core Portfolio - In Detail

Date:

Cantor Core Portfolio	
Performance YTD	%
Portfolio	-1.7%
Benchmark	0.7%
Relative Performance	-2.5%
P/E Ratio	18.5x
Dividend Yield	2.4%
ESMA Rating	6
Beta	1.01

13/10/2018			
Sectors Weights	Portfolio	Benchmark	+/-
Consumer Discretionary	11%	12%	
Consumer Staples	5%	10%	
Energy	5%	7%	
Financials	19%	18%	
Health Care	10%	13%	
Industrials	22%	12%	
Information Technology	16%	14%	
Telecommunication Services	0%	3%	
Utilities	0%	3%	
Materials	12%	6%	
Real Estate	0%	2%	

CANTOR Fitzgerald		
FX	Portfolio	Benchmark
EUR	58%	44%

EUR	58%	44%
GBP	21%	16%
USD	21%	40%

	Currency YTD %
GBP	0.71%
USD	3.77%

Weighted Average Contribution

Benchmark

Benchmark							Weighted	Average Co	ontribution
Index	Currency	PE	Outlook	Weighting	YTD Return (EUR)	Weekly Return	Price	Total	Contribution
STOXX Europe 600	EUR	16	Neutral	60%	-4.9%	-3.2%	376.8	-3.0%	
S&P 500	USD	20	Neutral	40%	9.2%	-1.7%	2,902.6	3.7%	
Total				100%					0.7%

Core Portfolio

Stock	Currency	Yield*	Hold /Sold	Sector	Weighting	Total Return Local	Weekly Return	Price	Total	Contribution
Glanbia Plc	EUR	1.6	н	Consumer Staples	5%	-2%	-0.1%	14.80	-0.1%	
Ryanair Holdings Plc	EUR	0.0	н	Consumer Discretionary	5%	-24%	-0.8%	11.87	-1.2%	
Industria De Diseno Textil	EUR	3.1	н	Consumer Discretionary	6%	-15%	-0.4%	25.41	-0.9%	
Lloyds Banking Group Plc	GBp	5.6	Н	Financials	5%	-10%	-0.1%	58.93	-0.5%	
Bank Of Ireland	EUR	0.0	н	Financials	5%	-8%	-0.8%	6.76	-0.4%	
Allianz Se	EUR	4.6	н	Financials	5%	-1%	-0.2%	193.04	-0.1%	
Facebook Inc*	USD	0.0	н	Information Technology	2%	-7%	-0.1%	157.33	-0.3%	
Paypal Holdings Inc*	USD	0.0	н	Information Technology	4%	-10%	-0.4%	83.18	0.6%	
Alphabet Inc*	USD	0.0	н	Information Technology	3%	-7%	0.0%	1,167.83	0.5%	
Amazon.Com Inc*	USD	0.0	н	Information Technology	4%	-11%	0.0%	1,889.65	2.7%	
iShares STOXX Europe 600 Banks ETF	EUR	3.5	S	Financials	5%	-12%	-0.1%	15.30	-0.6%	
Siemens Ag	EUR	3.4	н	Industrials	6%	-11%	-0.5%	105.40	-0.7%	
Vinci Sa	EUR	3.2	Н	Industrials	5%	-8%	-0.2%	80.84	-0.4%	
Smurfit Kappa Group Plc	EUR	2.6	Н	Materials	6%	4%	-1.4%	32.16	0.3%	
Allied Irish Banks Plc	EUR	2.5	Н	Financials	4%	-18%	-0.4%	4.50	-0.7%	
CRH Plc	EUR	2.5	Н	Materials	6%	-10%	-0.3%	28.25	-0.6%	
Kingspan Group Plc	EUR	1.0	н	Industrials	5%	11%	-0.4%	41.08	0.5%	
Royal Dutch Shell Plc	GBp	5.3	Н	Energy	5%	4%	0.0%	26.35	0.3%	
DCC Plc	GBp	2.0	н	Industrials	6%	-13%	-0.7%	68.60	-0.7%	
Microsoft Corp	USD	1.6	н	Information Technology	4%	-4%	-0.2%	112.13	-0.2%	
UnitedHealth Group Inc	USD	1.3	н	Health Care	5%	-2%	-0.1%	269.20	-0.1%	
Glaxosmithkline Plc	GBp	5.2	Н	Health Care	5%	13%	-0.2%	15.07	0.7%	
Total					100%					-1.7%

*Red Denotes Deletions

*Green Denotes Additions

*Stock has been reweighted

Yields are based on the mean of analyst forcast

All data taken from Bloomberg up until 12/10/2018.

Warning : Past performance is not a reliable guide to future performance

Warning : The value of your investment may go down as well as up.

*Red Denotes Deletions *Green Denotes Additions

*Yields are based on the mean of analyst forcast

From the News - Monday's Headlines

- Global Yi Says PBOC Considering Risks as He Plays Down Yuan Moves
- US Pastor Brunson back in US after Turkey bows to US pressure
- Europe Bavarian Vote Results Worse for European Stock-Haven Seekers
- UK Pound Weakens as Brexit Talks Fail to End Deadlock
- Ireland Greencore to sell out of US market in \$1.1bn deal

This Weeks Market Events

Monday	Tuesday	Wednesday	Thursday	Friday
Corporate	Corporate	Corporate	Corporate	Corporate
Bank of America Rio Tinto Schroders	Netflix Morgan Stanley Goldman Sachs Blackrock UnitedHealth Group Johnson & Johnson BATs	ASML Holdings US Bancorp Roche Barratt Developments Danone	PayPal Bank of New York Mellon SAP Norvartis Nestle Unilever	Schlumberger Procter & Gamble Volvo State Street
Economic	Economic	Economic	Economic	Economic
JP Industrial Production DE Import Prices IE Balance of Trade US Retail Sales	CN Inflation Rate GB Unemployment EA Zew Economic Sentiment DE Zew Economic Sentiment US Industrial Production	GB Retail Prices GB Inflation Rate EA Core Inflation Rate US Housing Starts	JP Balance of Trade DE Wholesale Prices GB Retail Sales US Initial Jobless Claims	JP Core Inflation CN Q3 GDP CA Inflation Rate US Existing Home Sales

Upcoming Events

22/10/2018 Ryanair, Luxottica Group	22/10/2018 IE Wholesale Prices,
23/10/2018 Swedbank, Verizon, Caterpillar, Vinci	23/10/2018 GB BusinessOptimism, EA Consumer Confidence
24/10/2018 Microsoft, Ford, Deutsche Bank, Barclays	24/10/2018 DE Manufacturing PMI, EA Loan Growth
25/10/2018 Alphabet, Shire, C&C, Daimler, Amazon, Lloyds	25/10/2018 ECB Rate Decision, Bank of Ireland
26/10/2018 IAG, TOTAL, Amundi, Bankinter, RBS, BASF	26/10/2018 DE Consumer Confidence, US Q3 GDP Growth

All data sourced from Bloomberg

Cantor Publications & Resources

Daily		CANTUR Tiligerald			
		Maning 28 ⁴ releases 281			
Contents	Market Vie				
Reter New Poster 15 sectored Mercey Brought & Earlien Ko- reering Smartil Kappic Gran- pernier Mercey Jik	 - Success study networks are specify sight the means, shorp instant hore a vary storag class site (5) means of specific sequences and an experimental sequences are specific sequences and a specific sequences are specific sequences and an experimental sequences are some and a specific sequences are specific sequences and an experimental table sequences are specific sequences and an experimental sequences are specific and a specific sequences are specific sequences and an experimental and a specific sequence are specific sequences and an experimental and a specific sequence are specific sequences and an experimental sequences are of the specific sequences are specific sequences are specific sequences and an experimental and a specific sequences are specific sequences and an experimental sequences are of the specific sequences are specific sequences and an experimental sequences are of the specific sequences are specific sequences are specific sequences are specific sequences are specific are specific sequences are specific sequences are are specific sequences are specific seq				
Introp protecting Belaks (VC) sourcep- attents, continued researching	Benartiti Cappa - Chaperlant	 Ynderline, Joseff, Joseff, James B., armen, Johns av, En Lander, H. 			
Itah Papers Today	Panine Oten Q1.8	 Yes having an integrate or input the fact starting at the start - Yes from through a uncertainty to taking at a vehicle of descent classed at Price. Set levels are appendix at second to relate a coming starting which should be appendix of Simulfits them are as an appendix of Simulfity and a second to a second to relate a coming starting which should be appendix of Simulfits them are as a second secon			
BCR shart New Drop's out to out often poor commence data (The birth Traves)		Construct: Brown Network's Act Proce results on the 10th (Astronomy, when inclused is only particles and of results. This have stress times in transmit 3VIs grantines, seeding in the stress time and the transmitteness of the Privile sector is Ada, Viscouth Both Botte is significant to relating particular disease. In an event will be added also 2VIs diseased is the stress of the Privile sectors.			
Claire seriegie his Indeel us marakshing pers sites (The bish belops den)		prod all leader all a TV- descer is in our holes: 3 year arrange 10 in the descer descer constraint arrange prod is the formal RMI pands separate outputs and the transmission of the basis RMI pands and and a second term transmission of the basis form was apportent and separa membrane in addition in RTMI basis form was apportent and separa membrane in a addition in RTMI basis form was apportent and separa membrane in a addition basis form was apportent and separa membrane in a addition basis for output and and a second term transmission of the second sec			
Dates is successful participally total market information (Plan Mark Transic)		Evaluat tools of the provide at 5.8% to 711%, weaked to 16 in measured cash personial ability, with a Free Cash Free (707) part 7.3%. These Galls (to contrast location			
Hereafored Papers Today	Dalara - pian Romalj Nacional Char 64.12	 Inder group Debits releases fol pair 2015 sentings fits more shoning contrast convertion. UPI rule shoup it 00.06, annual of conversion for 0.187, of more and one into interact CODe. 			
Longoon stadio kin Malani rana Changai Longo		 Neroperant and un solution that Failing is the line has mentioned has been stronger than expected in helicity and is the with expected in the UK, noting Deriving an exception. 			
Ex-Paragente (20) References except an arror ver dragen (Ref Roof Jacob) Restlict come of		Conserver: Millio III and an and conserve on Electron & electron inter- ers are these match as and match. Her mailmain parts on pages answering ACMES without to the sam white Comp. Service management of ALM driver premarily to an calific a servinge cases take of 127%, hit has an an an an an an and the ALM base managements and and 127% and 127%.			
Banha ranof argen d'best d'hensid Treat		En active, samplement unit that property is there are repor- levered data torus new printip who made that latering variance in tions a separate program wave translated samplement by the Google- hate is, 20% newsrated, Despite this is suit that the operime to re- appendicular messas way torug and expect in Mb level senant 13 Mb r-1308.			
ania comunitageneità Tatiles diSantarindani		Date (chy) is estimate budyer			

Daily Note

Each day we produce a market commentary outlining critical economic and company developments. We leverage off our global network of analysts and investment professionals to provide clients with critical insights from our local teams first thing in the morning.

Click Here



Investment Forum

Through our investment Forum we bring you the latest market news, investment insights and a series of informative articles from our experts.

Click Here

Regulatory Information

Issuer Descriptions: (Source: Bloomberg)

Bank of Ireland: Bank of Ireland provides a range of banking, life insurance and other financial services to customers in Ireland and United Kingdom **AIB:** Allied Irish Banks plc (AIB) attracts deposits and offers commercial banking services. The Bank offers mortgage, automobile, business, plant and equipment purchase, and lease financing loans, investment banking, securities brokerage, asset management and treasury services, and discounts invoices. AIB operates in Ireland, the United Kingdom, and the United States

Inditex: Industria de Diseno Textil, S.A. designs, manufactures and distributes apparel. The company operates retail chains in Europe, the Americas, Asia and Africa.

Ryanair: Ryanair Holdings plc provides low fare passenger airline services to destinations in Europe.

ICG: Irish Continental Group plc markets holiday packages and provides passenger transport, roll-on and roll-off freight transport, and container lift on and lift-off freight services between Ireland, the United Kingdom and Continental Europe.

Siemens: Siemens AG is an engineering and manufacturing company. The Company focuses on four major business sectors including infrastructure and cities, healthcare, industry and energy.

Lloyds: Lloyds offers a range of banking and financial services including retail banking, mortgages, pensions, asset management, insurance services, corporate banking and treasury services.

Allianz: Allianz, through it subsidiaries, provides insurance and financial services.

Facebook: Facebook Inc. operates a social networking site.

PayPal: PayPal operates a technology platform that enables digital and mobile payments on behalf of customers and merchants.

Alphabet: Alphabet provides web based search, advertisement, maps, software applications, mobile operating systems, consumer content and other software services.

Ryanair: Ryanair Holdings plc provides low fare passenger airline services to destinations in Europe.

Amazon: Amazon is an online retailer that offers a wide range of products.

Smurfit Kappa: Smurfit Kappa manufactures paper packaging products.

CRH: CRH is a global building materials group.

Kingspan: Kingspan is a global market player in high performance insulation and building envelope technologies.

DCC: DCC is a sales, marketing, distribution and business support services company.

GlaxoSmithKline: GSK is a research based pharmaceutical company.

Glanbia: Glanbia plc is an international dairy, consumer foods, and nutritional products company. The Company conducts operations primarily in Ireland, the United Kingdom, and the United States

JP Morgan: JPMorgan provides global financial services and retail banking.

Morgan Stanley: Morgan Stanley is a bank holding company, provides diversified financial services on a worldwide basis.

UnitedHealth Group: Incorporated owns and manages organized health systems in the United States and internationally

Wells Fargo: Wells Fargo is a diversified financial services company

Greencore: Greencore manufactures and distributes a diverse range of primary foods and related products, food ingredients and prepared foods to the consumer and industrial sectors

Kerry Group: is a major international food corporation. The Group develops, manufactures, and delivers innovative taste solutions and nutritional and functional ingredients.

VINCI SA: VINCI is a global player in concessions and construction with expertise in building, civil, hydraulic, and electrical engineering GlaxoSmithKline: GSK is a research based pharmaceutical company.

None of the above recommendations have been disclosed to the relevant issuer prior to dissemination of this Research.

Historical Record of recommendation

UnitedHealth Group: We have had an outperform rating on UnitedHealth Group since 09/07/2018

JP Morgan: We do not currently have a rating on this stock.

Morgan Stanley: We do not currently have a rating on this stock.

Wells Fargo: We do not currently have a rating on this stock.

Greencore: We revised our recommendation for Greencore from Outperform to Under Review, as of 15/10/2018

DCC: We have an Outperform on DCC as of 17/8/15 changing to Outperform from Not Rated

Glanbia: We changed our rating on Glanbia from Under Review to Outperform on 06/03/2018

Kerry Group: We have an "Outperform" rating on Kerry as of 16/11/2016.

VINCI SA: We initiated coverage of Vinci SA with an Outperform rating, on 25/08/2017.

GlaxoSmithKline: We moved our rating from Outperform to Market Perform on the 26/10/2017



Dublin: 75 St. Stephen's Green, Dublin 2. Tel: +353 1 633 3633. **email :** <u>ireland@cantor.com</u> **web :** <u>www.cantorfitzgerald.ie</u>

Regulatory Information

All regulatory disclosures pertaining to valuation methodologies and historical records of the above recommendations can be found on the Cantor Fitzgerald Ireland website here:

http://www.cantorfitzgerald.ie/research_disclosures.php

Cantor Fitzgerald Ireland Limited ("Cantor Ireland") is regulated by the Central Bank of Ireland. Cantor Fitzgerald Ireland Ltd is a member firm of the Irish Stock Exchange and the London Stock Exchange.

This communication has been prepared by and is the sole responsibility of Cantor Fitzgerald Ireland Limited of 75 St Stephens Green, Dublin 2, which is an authorised person for the purposes of the European Communities (Markets in Financial Instruments) Regulations 2007 (as amended) in Ireland or the Financial Services and Markets Act 2000 in the United Kingdom.

This material is approved for distribution in Ireland by Cantor Fitzgerald Ireland Ltd. It is intended for Irish retails clients only and is not intended for distribution to, or use by, any person in any country where such distribution or use would be contrary to local law or regulation. Cantor Fitzgerald Ireland Ltd ("CFIL") is regulated by the Central Bank of Ireland. Cantor Fitzgerald Ireland Ltd is a member firm of the Irish Stock Exchange and the London Stock Exchange.

Where CFIL wishes to make this and other Cantor Fitzgerald research available to Retail clients, such information is provided without liability and in accordance with our terms and conditions that are available on the CFIL website.

No report is intended to and does not constitute a personal recommendations or investment advice nor does it provide the sole basis for any evaluation of the securities that may be the subject matter of the report. Specifically, the information contained in this report should not be taken as an offer or solicitation of investment advice, or to encourage the purchased or sale of any particular security. Not all recommendations are necessarily suitable for all investors and CFIL recommend that specific advice should always be sought prior to investment, based on the particular circumstances of the investor either from your CFIL investment adviser or another investment adviser.

Where CFIL wishes to make this and other Cantor Fitzgerald research available to Retail clients, such information is provided without liability and in accordance with our terms and conditions that are available on the CFIL website.

CFIL takes all responsibility to ensure that reasonable efforts are made to present accurate information but CFIL gives no warranty or guarantee as to, and do not accept responsibility for, the correctness, completeness, timeliness or accuracy of the information provided or its transmission. This is entirely at the risk of the recipient of the report. Nor shall CFIL, its subsidiaries, affiliates or parent company or any of their employees, directors or agents, be liable to for any losses, damages, costs, claims, demands or expenses of any kind whatsoever, whether direct or indirect, suffered or incurred in consequence of any use of, or reliance upon, the information. Any person acting on the information contained in this report does so entirely at his or her own risk.

All estimates, views and opinions included in this research note constitute Cantor Ireland's judgment as of the date of the note but may be subject to change without notice. Changes to assumptions may have a material impact on any recommendations made herein. Unless specifically indicated to the contrary this note has not been disclosed to the covered issuer(s) in advance of publication.

Past performance is not a reliable guide to future performance. The value of your investment may go down as well as up. Investments denominated in foreign currencies are subject to fluctuations in exchange rates, which may have an adverse effect on the value of the investments, sale proceeds, and on dividend or interest income. The income you get from your investment may go down as well as up. Figures quoted are estimates only; they are not a reliable guide to the future performance of this investment.

Conflicts of Interest & Share Ownership Policy

It is noted that research analysts' compensation is impacted upon by overall firm profitability and accordingly may be affected to some extent by revenues arising other Cantor Ireland business units including Fund Management and Stock broking. Revenues in these business units may derive in part from the recommendations or views in this report. Notwithstanding, Cantor Ireland is satisfied that the objectivity of views and recommendations contained in this note has not been compromised. Nonetheless Cantor Ireland is satisfied that the impartiality of research, views and recommendations remains assured.

Our conflicts of interest management policy is available at the following link; https://cantorfitzgerald.ie/client-services/mifid/

We have assessed the publication and have classed it as Research under MIFID II. All charges in relation to this publication will be borne by Cantor



Dublin: 75 St. Stephen's Green, Dublin 2. Tel: +353 1 633 3633. email : ireland@cantor.com web : www.cantorfitzgerald.ie